- Home
- BRNS vs KZR Comparison
BRNS vs KZR Comparison
Compare BRNS & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.69
HOLD
Current Price
$6.29
Company Overview
Basic Information| Metric | BRNS | KZR |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 45.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRNS | KZR |
|---|---|---|
| Price | $0.69 | $6.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 101.8K | 36.0K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1766.46 | N/A |
| 52 Week Low | $0.64 | $3.53 |
| 52 Week High | $2.92 | $7.04 |
Technical Indicators
Market Signals| Indicator | BRNS | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 58.70 |
| Support Level | $0.66 | $6.23 |
| Resistance Level | $0.78 | $6.37 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 7.88 | 59.37 |
Price Performance
Historical Comparison BRNS
KZR
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.